Introduction
The use of left ventricular assist devices (LVADs) has revolutionized the treatment of advanced heart failure (HF) and is increasingly used as a bridge to heart transplantation or as destination therapy. 1 In a minority of patients, chronic mechanical unloading with an LVAD has been shown to result in significant reverse remodelling with improved myocardial structure and function, such that these patients can be weaned from mechanical support with sustained myocardial recovery. 2 -4 The molecular, cellular and clinical characteristics that define such patients are being investigated in order that they can be better targeted, but the role of neurohormonal blocking medical therapy in this process is not well understood. 5, 6 In chronic HF, cardiac remodelling is driven largely by pressure and volume overload of the left ventricle 7 and the reversal of this negative remodelling by chronic mechanical unloading has been shown on molecular, cellular and organ levels. 6, 8, 9 In addition to this haemodynamic stimulus, the up-regulation of the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system in chronic HF contributes to the remodelling and fibrosis seen in chronic dilated cardiomyopathy. 10 Inhibition of the RAAS with angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs) and aldosterone antagonists, and of the sympathetic nervous system with beta-blockers in chronic HF leads to significant improvements in morbidity and mortality and reverse cardiac remodelling. 11 Such therapies are often used concurrently with chronic mechanical unloading, despite a lack of data. The International Society for Heart and Lung Transplantation mechanical circulatory support (MCS) guidelines state that beta-blockers may be used for hypertension or for rate control in patients with tachyarrhythmias, ACEIs/ARBs may be used for hypertension or for risk reduction in patients with vascular disease and diabetes, and mineralocorticoid receptor antagonists may be used to limit the need for potassium repletion in patients with adequate renal function and for potential beneficial anti-fibrotic effects on the myocardium. 12 All of these recommendations are based upon expert consensus (level of evidence: C).
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A few small studies have evaluated the use of neurohormonal blocking therapies in the setting of chronic mechanical unloading with LVADs. 2, 3, 13 These studies found that varying but significant proportions of patients experienced reverse remodelling and that some of these were able to undergo LVAD explantation subsequent to sufficient recovery of the native heart structure and function. However, these studies were small in size and did not compare the use of HF medications with chronic LVAD unloading alone. In fact, the use of neurohormonal blocking therapies in chronic LVAD patients has never been compared with pure LVAD unloading alone (without concurrent HF medications). In the present study, the effects of standard HF therapy compared with no anti-remodelling medications on myocardial structure and function, as well as the peripheral organ effects of these two strategies, in the setting of chronic LVAD, were prospectively investigated.
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Pharmacological therapy
Treatment with a specific class of HF medical therapy was defined as the administration of a medication for at least 2 months during LVAD therapy; lowest daily doses were defined as: 6.25 mg of carvedilol; 25 mg of metoprolol; 5 mg of lisinopril; 25 mg of captopril; 25 mg of losartan; 80 mg of valsartan, and 12.5 mg of spironolactone. Patients in the No Meds group (n = 44) did not take any neurohormonal blocking agent during chronic LVAD therapy. Patients who were taking one or two neurohormonal blocking medical therapy agents were excluded: 86 patients were using a beta-blocker; 63 patients were using an ACEI or ARB, and 67 patients were using an aldosterone antagonist. Among the 37 patients in the Meds group, 33 patients were treated with carvedilol [mean ± standard deviation (SD) daily dose: 29.3 ± 17.6 mg], four patients were treated with metoprolol (mean ± SD daily dose: 37.5 ± 12.5 mg); 35 patients were treated with lisinopril (mean ± SD daily dose: 12.7 ± 8.5 mg); one patient was treated with captopril (daily dose: 25 mg); eight patients were treated with losartan (mean ± SD daily dose: 42.2 ± 37.8 mg); one patient was treated with valsartan (daily dose: 80 mg); 35 patients were treated with spironolactone (mean ± SD daily dose: 23.1 ± 7.1 mg), and two patients were treated with eplerenone (mean ± SD daily dose: 62.5 ± 37.5 mg).
Clinical data and follow-up period
Patients were followed for 1 year or until heart transplantation (whichever took place first). Demographic, medication, co-morbidity and laboratory data were collected within 1 week prior to LVAD implantation and during LVAD support. Clinical events including side effects observed during LVAD support were prospectively captured using the standardized Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) definitions. 14 These included pump failure, bleeding, pump thrombosis, neurological event/cerebrovascular event, infection, arrhythmia, chronic renal failure, liver failure, tamponade, ventricular arrhythmia, and pneumothorax. Late right ventricular failure was defined according to the occurrence of one of the following three events at >4 weeks after LVAD implantation: (i) central venous pressure of >18 mmHg and a cardiac index of <2 L/min/m 2 in the absence of elevated left atrial pressure; (ii) requirement for a right ventricular assist device, and (iii) requirement for inhaled nitric oxide or inotropic support for >1 week.
Assessment of cardiac structure and function
Right heart catheterization was performed within 1 week preceding LVAD implantation and within 6-8 weeks after implantation in order to document the adequacy of left ventricular (LV) unloading and to obtain invasive haemodynamic data. Transthoracic echocardiography was performed within the 2 weeks prior to LVAD implantation, and then at months 1, 2, 3, 4 and 6 after implantation. Appendix S1 includes a comprehensive description of the serial echocardiographic evaluation protocols. All echocardiograms were assessed by two independent readers (A.B.C., O.W.-P.). In order to evaluate the reliability of the study measurements, inter-and intra-observer variability were tested in both readers.
Myocardial tissue acquisition and whole-field digital microscopy histopathological analysis
Myocardial tissue samples were obtained in patients pre-and post-LVAD unloading. Tissue was collected from the LV apical core at LVAD implantation and at heart explantation at the time of transplantation or at LVAD explantation. Control samples were acquired from the apex of normal donor hearts. Full-thickness epicardium-to-endocardium tissue slices were fixed in 10% buffered formalin for 24 h and then processed to paraffin embedding to be used for histochemical stains. All of these samples were processed and analysed in a central laboratory at the Eccles Institute of Human Genetics, University of Utah. Appendix S1 includes a comprehensive description of the tissue acquisition and digital microscopy protocols for epicardium-to-endocardium assessment of interstitial, perivascular and total fibrosis.
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Statistical analysis
Standard summary descriptors were used, including frequencies, percentages and means. Measures of variation were presented as the SD or standard error of the mean (SEM Comparisons of results between patients with and without neurohormonal medications for LV ejection fraction (LVEF) and LV end-diastolic diameter (LVEDD) at baseline were performed using general linear mixed models with repeated measures for the six repeat measurements of these factors (baseline and at months 1, 2, 3, 4 and 6). Adjustments for potential confounders were performed across multiple models that added one to three covariables at a time to the linear model, given the limited sample size, with covariables constituted of age, sex, hypertension, diabetes, tobacco use, atrial fibrillation, duration of HF symptoms, baseline creatinine, baseline cardiac index, baseline New York Heart Association (NYHA) class, LVAD indication, INTERMACS profile, and HF aetiology. A two-tailed P-value of <0.05 was considered to indicate statistical significance. All analyses were performed using STATA version 13.0 (StataCorp LP, College Station, TX, USA) or IBM SPSS Statistics for Windows version 23.0 (IBM Corp., Armonk, NY, USA).
Results
Patient characteristics before left ventricular assist device implantation
The baseline characteristics of patients in the No Meds and Meds groups are shown in Table 1 . The majority of patients in both groups were male (82% and 76% in the No Meds and Meds groups, respectively). Patients in the No Meds group were older (mean ± SD age: 57 ± 12 years vs. 48 ± 19 years; P = 0.01) and were more likely to have ischaemic cardiomyopathy (52% vs. 27%; P = 0.02) than those in the Meds group. Duration of HF, NYHA class and baseline LV function were similar between the two groups. Both groups had similar proportions of patients on beta-blocker therapy (No Meds 68% vs. Meds 65%; P = NS) and ACEI or ARB treatment (No Meds 66% vs. Meds 65%; P = NS) prior to LVAD implant. There was greater aldosterone antagonist use in the Meds group (76% in the Meds group vs. 46% in the No Meds group; P = 0.003). Pre-LVAD implantation use of inotropic support was similarly high in both groups (80% in the No Meds group vs. 70% in the Meds group; P = NS) and there were no significant differences in INTERMACS profile. Although there was a trend towards greater use of LVADs as destination therapy in the Meds group, the main indication for LVAD implantation in both groups was as a bridge to transplantation (84% in the No Meds vs. 68% in the Meds group). To control for baseline differences, multivariate analysis controlling for age, sex, hypertension, diabetes, tobacco use, atrial fibrillation, duration of HF symptoms, baseline creatinine, baseline cardiac index, baseline NYHA class, LVAD indication, INTERMACS profile and HF aetiology was performed.
Haemodynamic and biochemical profiles of subjects before left ventricular assist device implantation
The baseline haemodynamic and biochemical characteristics of patients are shown in Table 1 . Patients in the No Meds group had a 
Effects of left ventricular assist device unloading and neurohormonal blockade on myocardial structure and function
Supplementary material online, Table S2 , shows the time course and magnitude of changes in myocardial structure during LVAD mechanical unloading. The LVEF improved over time in both groups and to the point of statistical significance in comparison with pre-LVAD baseline values in each group at the 1-and 2-month time-points in the No Meds group (P < 0.05) and at the 3-, 4-and 6-month time-points in the Meds group (P < 0.05). There was no significant difference between the groups in the change in LVEF over the course of 6 months. Findings were unchanged after multivariate analysis controlling for age, sex, hypertension, diabetes, tobacco use, atrial fibrillation, duration of HF symptoms, baseline creatinine, baseline cardiac index, baseline NYHA class, LVAD indication, INTERMACS profile, and HF aetiology. Figure  1A Table S2 ). Significant reductions in LVEDD were seen in both groups over time in comparison with baseline values and were significant at each time-point examined. In the Meds group, reductions were significantly greater than in the No Meds group. This difference was seen within 1 month of LVAD implant and was sustained for the 6-month duration of the study (P < 0.05 for all comparisons; Figure 1B) . This difference was maintained even after adjustment for potential confounders (age, sex, hypertension, diabetes, tobacco use, atrial fibrillation, duration of HF symptoms, baseline cardiac index, baseline NYHA class, LVAD indication, INTERMACS profile, and HF aetiology) except in models entering creatinine, which reduced the significance of the difference between medication groups to a P-value of 0.07 for LVEDD rather than of < 0.05 as was true for other noted covariables. Left ventricular end-diastolic volume index (LVEDVI) decreased significantly over time in both the No Meds and Meds groups in comparison with baseline values, again with a significant difference between the two groups in ΔLVEDVI, favouring the Meds group at 1 month and at 6 months (P < 0.05) ( Figure 1C) . Figure 1D shows the LV end-systolic volume index (LVESVI) over time. There was a significant improvement from baseline within each group, but there were no significant differences between the groups at any time-point. Figure 1E shows the LV mass index (LVMI) over time, which also decreased significantly in comparison with baseline values within each group at months 1 and 2 (P < 0.05). However, beyond 2 months, a significant decrease in LVMI was seen only in the Meds group and was noted at all time-points (P < 0.05). Additionally, diastolic function and degree of mitral insufficiency were compared between the Meds and No Meds groups over time. No significant difference in diastolic function or degree of mitral insufficiency emerged between the two groups over time (supplementary material online, Table S3 ).
In view of the large proportion of patients with ischaemic cardiomyopathy in the No Meds group, a subanalysis of the non-ischaemic patient population was performed to compare the roles of Meds vs. No Meds. These data are presented in the supplementary material online, Table S4 . Findings were similar to those presented above in the full cohort of No Meds and Meds patients, although the difference between the two groups was even more pronounced in the Meds group. In the non-ischaemic cohort, there were no differences between the two groups at baseline. The LVEF improved significantly from baseline in the Meds group at 1, 3 and 4 months, but only at 1 month in the No Meds group. This difference between the two groups was statistically significant and favoured the Meds group at 3 and 4 months. The LVEDD showed a significant reduction in both the No Meds and Meds groups between baseline and months 1 and 2. In the Meds group this significant reduction was seen at all time-points (additionally at months 3, 4 and 6). Furthermore, in the Meds group, this reduction was significantly greater than in the No Meds group at 3, 4 and 6 months. Values for LVEDVI and LVESVI improved within both groups between baseline and 1 month, but only in the Meds group at the subsequent time-points. This difference between the two groups was statistically significant at 3 and 4 months, favouring the Meds group. Lastly, the LVMI also reduced over time compared with baseline values but the reduction was significant only in the Meds group, although this was notable at all time-points. Differences between the two groups were significant only at 4 months.
Biochemical and haemodynamic profiles of subjects after left ventricular assist device support
Biochemistry data were obtained at LVAD explantation for heart transplantation or after 1 year of follow-up (whichever . 
Clinical events during left ventricular assist device support
Adverse effects during the LVAD support period (defined by INTERMACS definitions 14 ) did not differ significantly between the two groups ( Table 3 ). The most common side effects in both groups were bleeding (0.36 events/patient year in the No Meds group vs. 0.12 events/patient year in the Meds group; P = 0. Patient outcomes at 1 year (including those in patients who underwent transplantation, those who had LVAD explanted for myocardial recovery, those with continued LVAD and those who died) are shown in the supplementary material online, Table S5 . 
Changes in myocardial fibrosis during chronic left ventricular assist device unloading combined with neurohormonal blocking pharmacotherapy
Comparisons of percentages of fibrosis between pre-and post-LVAD time-points showed that LVAD support was not associated with any significant changes in interstitial, perivascular and total fibrosis. Figure 2A shows the effect of LVAD support on total fibrosis (interstitial and perivascular fibrosis results not shown) and demonstrates similar findings across the Meds and No Meds groups. Tissue samples could not be obtained in all patients within either the Meds group (n = 6, 16% of patients) or the No Meds group (n = 29, 66% of patients). Furthermore, patients with a high degree of fibrosis at the pre-LVAD time-point showed a trend towards decreased fibrosis during LVAD support, whereas patients with a lower degree of fibrosis showed no change. This phenomenon occurred in both the Meds and No Meds groups. To investigate this observation further, the fibrosis content in 14 donor control hearts was analysed (Appendix S1). As expected, the degree of myocardial total fibrosis in this relatively large donor cohort was variable (data not shown). Total myocardial fibrosis of 15% was identified as the upper cut-off value for normal total fibrosis in this donor cohort. Hence, in the present HF patients, a 'high fibrosis' subgroup was defined as patients with >15% total fibrosis at the pre-LVAD time-point and a 'low fibrosis' subgroup was defined as patients with <15% total fibrosis pre-LVAD. Figure 2B shows the effect of LVAD support on fibrosis in the high-fibrosis subgroup of patients. Interestingly, findings showed a trend towards decreased fibrosis following LVAD support in the high-fibrosis subgroups in both the Meds and No Meds groups. Figure 2C Figure S1 ).
Discussion
Effects of adjuvant neurohormonal blockade on myocardial structure and function
The present study is the first to directly compare the effects of HF drug therapy with those of LVAD unloading alone in patients with documented chronic dilated cardiomyopathy. It is also the largest human myocardial tissue study so far to report on the highly controversial issue of the effect of LVAD unloading on myocardial fibrosis. There is significant variation in clinical practice regarding the use of conventional HF drugs following LVAD implantation. Additionally, rates of improvement in myocardial structure and function following LVAD unloading vary widely. Compared with rates in prospective LVAD bridge-to-recovery studies, 2,3,5,13,16 rates of myocardial improvement were low in retrospective studies 16 and post hoc queries of multicentre LVAD trials and registries, such as INTERMACS, 14, 16 that were designed to examine primarily real-world applications such as bridge-to-transplantation and destination therapy.
In studies in which neurohormonal blocking therapies are used, myocardial recovery appears to be even higher. In a study published in 2006 that examined myocardial recovery in non-ischaemic cardiomyopathy (NICM) with LVAD and neurohormonal blocking therapy, the Harefield investigators reported a 73% rate of sustained myocardial recovery with the use of high doses of standard HF drugs and the 2 -adrenergic agonist clenbuterol. 3 Although this remarkable rate of recovery has been difficult to reproduce, the same group published a similar study utilizing . . . . . . . . . . . . . . the same protocol of aggressive pharmacological therapy and mechanical unloading and reported a 60% rate of myocardial recovery. 2 Similarly, the Montefiore group reported a myocardial recovery rate of 24% in patients with NICM treated with neurohormonal blocking therapies and chronic LVAD. 13 All three of these studies specifically focused on NICM and used high-dose HF drug therapy, 2,3,13 which many patients cannot tolerate. The current study is the first to prospectively assess the use of such HF drug therapies administered at 'real-life' doses in patients with a range of cardiomyopathy aetiologies, including ischaemic cardiomyopathy. Its findings emphasize that both mechanical unloading and pharmacological therapy contribute to cardiac reverse remodelling and that the addition of neurohormonal blockade, even at modest doses, appears to exert additional reverse remodelling benefits beyond the effects of chronic LVAD unloading itself. In the first 2 months, LV diameter decreased in both groups, but over the course of the remaining 4 months, LV diameter decreased more significantly in the Meds group. Similarly, LV mass decreased in both groups in the first 2 months and continued to do so in patients treated with neurohormonal blockade. Importantly, the mass did not decrease beyond normal ranges to suggest hypertrophy regression to the point of myocardial atrophy and degeneration.
17 Furthermore, a subanalysis of the non-ischaemic subset of patients (to control for the confounding of findings by ischaemic cardiomyopathy patients) suggests similar findings and demonstrates even more significant improvements in cardiac structure and function over time in the Meds group compared with the No Meds group. The present findings suggest that initially LVAD unloading itself contributes to reversal of the pressure and volume overload of the chronically dilated ventricle, but that over the next several months pharmacological therapy may start to exert important anti-remodelling effects. LVAD unloading has been shown to lead to improvements in myocardial structure and function, as well as to decrease mass as early as 30 days following implantation. 17, 18 Similarly to the present findings, Klotz et al. 19 demonstrated in a small study that ACEI therapy during chronic LVAD support enhances reverse structural remodelling in the left ventricle (as shown by decreases in LV size and mass) and decreases myocardial stiffness during a 3-month period. The time course for LV remodelling generally observed with beta-blockers, ACEIs and ARBs in the absence of LVAD falls into this timeframe. 20, 21 This study underlines the need for further investigation in prospective randomized controlled trials to elucidate the role of conventional HF drug therapy in the long-term care of LVAD patients.
Effect of adjuvant neurohormonal blockade on myocardial fibrosis
Investigations into the effects of LVAD unloading on the extracellular matrix and fibrosis have shown mixed results. 22 Most of these studies investigated the cardiac remodelling effects of first-generation pulsatile LVADs and some investigators specifically attributed their variable results to differences in background medications. 23, 24 For example, Klotz et al. 25 noted increased collagen deposition, collagen cross-linking and tissue angiotensin II following pulsatile LVAD support. The same group found that simultaneous treatment with RAAS blockade and chronic pulsatile LVAD support led to down-regulation of cardiac angiotensin levels 19 with decreased fibrosis and extracellular collagen deposition.
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Although there are few data evaluating the effects of beta-blockers on reverse cardiac remodelling following LVAD, Klotz et al. reported a seven-fold increase in serum norepinephrine levels following LVAD implantation, supporting the hypothesis that this sympathetic up-regulation is likely to represent a target for the beneficial effects of beta blockade. Others have reported marked sympathetic activation in continuous-flow LVAD patients, which also suggests beta-blockers may be beneficial in these patients. 28 The present findings indicate that in patients with baseline increased myocardial fibrosis pre-LVAD, the combination of chronic continuous-flow LVAD unloading and neurohormonal blocking pharmacotherapy leads to myocardial fibrosis regression. The observed decrease in myocardial fibrosis is even more convincing considering that many groups have universally reported a post-LVAD regression of hypertrophy in cardiomyocytes, 20, 24, 25 which comprise the main compartment of myocardial tissue. Therefore, the decrease in cardiomyocyte size might be expected to 'induce' a proportional relative increase in the extracellular matrix, which is the other major myocardial tissue compartment. This logic strengthens the argument that the present findings of decreased fibrosis indicate a real phenotype. Although such fibrosis regression was not seen in all patients treated with neurohormonal blockade, certain HF subpopulations with increased baseline fibrosis at the pre-LVAD time-point may benefit more from such a strategy. Further research is required to investigate this possibility in greater depth.
Effects of adjuvant neurohormonal blockade on peripheral organ function and systemic side effects
Concerns regarding the risk for possible end-organ side effects with pharmacological neurohormonal blockade during LVAD support have been expressed in view of the dramatic decreases in afterload and preload and potential for hypotension and hypovolaemia. In addition, reduction of LV size with anti-remodelling therapy has been postulated as a potential mechanism to increase the direct mechanical stimuli for inducing arrhythmias. The present findings indicate that these agents do not cause a statistically significant increase in adverse effects. However, because of its small sample size, the present study is not powered to identify differences in event rates for some adverse events. The current authors caution against the drawing of conclusions about safety and side effects based on this small study. However, it can be postulated that the haemodynamic support offered by LVAD may allow patients to tolerate vasoactive therapies that provide neurohormonal blockade that would otherwise not be possible and may allow for up-titration of such therapies to higher doses that are more likely to provide an anti-remodelling effect. These observations may help to explain the remarkable rates of myocardial recovery noted in prior studies of NICM patients when high doses of neurohormonal blockade can be achieved in the setting of chronic mechanical unloading.
2,3
Study limitations
The primary limitation of this study is the observational nature of the evidence and the fact that medical therapy was left to the discretion of the treating HF care provider. The Meds group included a higher proportion of patients with LVAD as destination therapy, which is likely to have contributed to the more aggressive use of HF therapies in this group. Additionally, baseline characteristics differed between the two groups in a way that suggests the No Meds group represented a sicker group of patients. However, the structural changes observed in LVEF and LVEDD remained consistent even after multivariate analysis controlling for such baseline differences. The follow-up period was limited to 1 year and the total number of patient observations decreased over time as a result of sporadic transplantation in this population. Differences between the two groups in pump speed and degree of unloading may have contributed to the structural changes observed. However, the limited data on average pump speed collected and analysed do not support this (data not shown). Lastly, the small size of the patient sample represents a limitation and may limit the authors' ability to detect certain differences. For instance, although there were no significant differences in adverse events between the two groups, it is unlikely that the study was sufficiently powered to detect such differences.
Conclusions
This prospective study of chronic systolic HF patients undergoing LVAD support demonstrates clinical and histopathological changes that suggest adjuvant HF drug therapy was associated with additional favourable effects on cardiac structure and function beyond the beneficial effects attributed to LVAD support alone. Adjuvant HF drug therapy did not appear to influence major post-LVAD adverse events observed during the follow-up period of this study.
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